San Diego, CA and Flagstaff, AZ, April 12, 2018: — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on mergers & acquisitions (M&A), strategic advisory, capital financing and valuation services, will seek to identify strategic partnerships and financial investors for the Company to progress their lead product Grizzly™ targeting pre-cancerous cells in the elimination of Barrett's Esophagus and Esophageal Adenocarcinoma, the fastest growing cancer worldwide.
Barrett’s Esophagus (BE) is a premalignant condition caused by stomach acid or gastrointestinal reflux disease (GERD) mutating healthy cells in the lower esophagus into Barrett’s cells. Approximately 90% of Esophageal Adenocarcinoma (EAC) patients do not receive a prior diagnosis of Barrett’s Esophagus (BE). BE affect’s more than 12 million American adults, and is associated with a 30-fold increased risk of developing EAC. This new treatment will provide an alternative to the Radiofrequency Ablation Technology (“RFA”) and cryoablation technologies currently in use for treatment of BE thereby reducing the number of episodes of treatment and providing unparalleled user control for adequate cell removal.